Two European countries have recently unveiled national strategies centered on ATMPs. These are critical frameworks, especially as the Netherlands grapples with similar challenges with its fragmented but promising ATMP ecosystem.
Denmark has just published a new Personalised Medicines Strategy with a strong focus on advanced and tailored therapies, aiming to prepare its system for future-ready, patient-centred innovation (link).
Germany earlier launched its National Strategy for Gene- and Cell-Based Therapies, a comprehensive plan that includes dedicated funding, a national network office, GMP facility coordination, and regulatory support to accelerate development and translation (link).
Both countries are clearly stepping up their national efforts to strengthen the ATMP ecosystem. With our strong science base but fragmented landscape, the Netherlands risks falling behind. Is it time we also define a national strategy and join this leap forward?